X
- No products in the list
The Pan-Myeloid NGS Panel truNGS® Kit provides a complete solution for the genetic profiling of myeloid malignancies. Covering 95 clinically significant genes, the panel detects single nucleotide variants (SNVs), insertions/deletions (Indels), and RNA fusions. It offers full exon coverage for 20 key genes, hotspot analysis for 34 markers, and fusion detection in 35 genes implicated in diseases such as AML, MPN, MDS, CML, CMML, and JMML.
Designed for use with blood and bone marrow samples, the kit requires 100–200 ng DNA and 400–500 ng RNA. Using hybrid capture technology, the workflow ensures comprehensive coverage, high uniformity, and reproducibility even for challenging targets like CEBPA, ASXL1, CALR, FLT3-ITDs, and KMT2A-PTDs.
The assay also includes hotspots in six pharmacogenomics genes (CYP3A4, CYP2C9, TPMT, MTHFR, NUDT15, ABCB1) to guide chemotherapy dose optimization. Combined with integrated bioinformatics, results are delivered within ~1.5 hours from FASTQ to clinical report.
Compatible with Illumina and MGI platforms, the Pan-Myeloid NGS Panel empowers hematology labs to deliver precise, actionable results that enhance diagnosis, prognosis, and treatment strategies in myeloid disorders.
The truNGS® Pan-Myeloid Panel Kit is a comprehensive sequencing solution designed for hematology and oncology laboratories. It profiles 95 genes associated with myeloid malignancies:
20 genes with complete exon coverage (e.g., RUNX1, TET2, TP53, ASXL1, EZH2).
34 genes covered via hotspot analysis (e.g., FLT3, JAK2, KRAS, IDH1, IDH2, NPM1).
35 genes monitored for RNA fusions (e.g., KMT2A, FGFR1, NUP98, PDGFRA).
The panel also includes hotspot variants in six pharmacogenomics genes (CYP3A4, CYP2C9, TPMT, MTHFR, NUDT15, ABCB1), ensuring treatment personalization. With a target region of 112 kb for DNA and 117 kb for RNA, it enables high-resolution variant detection.
Myeloid malignancies are genetically complex and clinically diverse. The Pan-Myeloid NGS Panel addresses this complexity by covering key alterations across multiple disease types:
AML (Acute Myeloid Leukemia) – FLT3-ITDs, NPM1, CEBPA.
MPN (Myeloproliferative Neoplasms) – JAK2, CALR, MPL.
MDS (Myelodysplastic Syndromes) – TP53, SF3B1, SRSF2, ASXL1.
CML (Chronic Myeloid Leukemia) – BCR-ABL1 fusions.
CMML/JMML – NRAS, KRAS, PTPN11.
By covering both driver mutations and pharmacogenomics hotspots, the panel provides a dual clinical advantage: accurate disease characterization and personalized therapy guidance.
The truNGS® Pan-Myeloid Panel is designed to deliver high performance in detecting difficult-to-sequence regions and rare alterations. Enhanced coverage ensures robust results for challenging genes like CEBPA, ASXL1, CALR, FLT3-ITDs, and KMT2A-PTDs.
Validated for use with blood and bone marrow samples, the panel requires 100–200 ng DNA and 400–500 ng RNA. It delivers reproducible results at mean coverage of 1000x with as little as 600 Mb sequencing data per sample. With a hands-on library preparation time of 1.5 days and streamlined reporting, the assay is optimized for efficiency.
The workflow consists of two main stages:
Library Preparation – DNA and RNA undergo fragmentation, adapter ligation, and PCR amplification.
Hybrid Capture and Target Enrichment – Libraries are pooled, hybridized with gene-specific probes, captured, and amplified.
Sequencing is performed on Illumina or MGI platforms using paired-end 150 × 2 chemistry. The included bioinformatics pipeline processes FASTQ files, aligns sequences, identifies SNVs, Indels, and fusions, and generates a clinical report in ~1.5 hours.
The Pan-Myeloid NGS Panel supports multiple clinical and translational applications:
Comprehensive diagnosis – Detect mutations driving AML, MPN, MDS, CML, CMML, and JMML.
Prognostic assessment – Stratify patients based on genetic alterations with established clinical significance.
Therapeutic guidance – Identify actionable mutations and pharmacogenomics hotspots to optimize treatment selection and dosing.
Research utility – Enable biomarker discovery and support clinical trials in hematology.
By delivering accurate, reproducible, and clinically actionable insights, the truNGS® Pan-Myeloid Panel enhances precision medicine approaches for myeloid malignancies.
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.